$The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma$

The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

Date : 2021-02-23 Views : 0

IASO BIO’s Cell Therapy Summit Forum Successfully Held in Nanjing

Date : 2020-12-21 Views : 0

IASO Bio Appoints Dr. Biao Zheng as Chief Scientific Officer and Dr. Wen Wang as Chief Medical Officer

IASO Bio is pleasant to announce the appointment of Dr. Biao Zheng as Chief Scientific Officer (CSO), and the appointment of Dr. Wen Wang as Chief Medical Officer (CMO).

Date : 2020-10-14 Views : 0

IASO Biotherapeutics Raises $60 Million in Series B Financing led by GL Ventures to Advance Cell Therapies for Cancer Care

Date : 2020-03-23 Views : 237

$NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio$

NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio

Date : 2019-09-11 Views : 232

$Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings$

Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

Date : 2019-06-18 Views : 221